Additional file 1 of Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study

Htoo, Phyo T.; Tesfaye, Helen; Schneeweiss, Sebastian; Wexler, Deborah J.; Everett, Brendan M.; Glynn, Robert J.; Schmedt, Niklas; Koeneman, Lisette; Déruaz-Luyet, Anouk; Paik, Julie M.; Patorno, Elisabetta

doi:10.6084/m9.figshare.25194735.v1

12933_2024_2150_MOESM1_ESM.docx (300.95 kB)

Additional file 1 of Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study

journal contribution

posted on 2024-02-09, 04:41 authored by Phyo T. Htoo, Helen Tesfaye, Sebastian Schneeweiss, Deborah J. Wexler, Brendan M. Everett, Robert J. Glynn, Niklas Schmedt, Lisette Koeneman, Anouk Déruaz-Luyet, Julie M. Paik, Elisabetta Patorno

Supplementary Material 1

Funding

Boehringer Ingelheim

History

Usage metrics

Keywords

Empagliflozin SGLT2i GLP-1RA Cardiovascular disease Type 2 diabetes Chronic kidney disease Effectiveness

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

Additional file 1 of Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study

Funding

Boehringer Ingelheim

History

Usage metrics

Categories

Keywords

Licence

Exports